Logo

Regulus

UCSD Researchers Win Grant to Develop Extracellular RNA Biomarker Panel for Glioma
Premium

The funding coincides with publication of reports from the Extracellular RNA Consortium outlining growth and challenges in exosomal RNA-based diagnostics.

Regulus Plans for New Clinical Trials, Third Drug Candidate in '15
Premium

The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year.

New Data Shows Higher Dose of Regulus HCV Drug Offers Better Viral Load Reductions
Premium

The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments.

Regulus Hits Milestone in Biogen Idec microRNA Biomarker Deal

Regulus said it was able to develop its miRNA extraction and profiling technology to meet the quality specifications set out by its partner.

Alnylam Publishes Paper on Development of GalNAc Conjugate Delivery Technology
Premium

The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.

Nov 24, 2014

Data Point to Regulus Alport Drug Use in Late-stage Disease, Other Kidney Diseases
Premium

Nov 6, 2014

Regulus Weighs Dual Development Track for HCV Drug
Premium

Nov 6, 2014

Regulus Closes $103.5M Stock Offering
Premium

Nov 6, 2014

Wall Street in October Proves Tumultuous for Four RNAi/microRNA Shops
Premium

Oct 30, 2014

Regulus to Raise $90M in Stock Offering
Premium

Oct 23, 2014

Regulus Stock Surges on Positive Phase I HCV Data; Phase II on Deck for 2015
Premium

Sep 25, 2014

Regulus Begins Natural History of Disease Study for Alport Syndrome
Premium

Aug 21, 2014

IP Update: Recent Patents Awarded to Alnylam, Baxter, GE Healthcare, and More
Premium

Aug 7, 2014

Regulus Sets Bar High for HCV Program, Sees Alport Drug in Phase II by 2015
Premium

Aug 5, 2014

Regulus, Biogen Ink New Agreement for Potential MS miRNA Biomarkers

Jul 24, 2014

Regulus Study Points to Possibility of Adverse Effects with Chronic miR-33 Inhibition
Premium

Jul 24, 2014

Regulus Receives Orphan Drug Designation for Alport Syndrome Drug
Premium

Jun 26, 2014

Microlin Lowers IPO Price Range as it Continues to Seek a Public Listing
Premium

Jun 26, 2014

People in the News: Paul Grint, Jennifer Doudna, Emmanuelle Charpentier
Premium

Jun 12, 2014

Regulus Weighs Spinoff of microRNA Biomarker Unit
Premium

May 15, 2014

Regulus Posts Increased Q1 Losses, Lower Revenues
Premium

Apr 10, 2014

Regulus Preclinical Data Shows Liver Cancer Biomarker Potential of microRNAs
Premium

Apr 9, 2014

At AACR, Researchers Highlight Multiple Roles of microRNAs in Cancer

Mar 6, 2014

Regulus Provides Details on AstraZeneca Alliance, In-house Pipeline Programs
Premium

Feb 20, 2014

Regulus Names Alport Syndrome as Next Pipeline Indication
Premium

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.